ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.574,68
1,55%
S&P 500
5.949,91
1,83%
Dow Jones
43.221,55
1,65%
Euro vs US Dollar
1,02871
-0,07%
Bitcoin
99.545,38
-0,97%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) News

SNGX

Soligenix (SNGX)

Soligenix Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SNGX
DatumZeitQuelleÜberschriftSymbolFirma
14/01/202513h30PR Newswire (US)HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
16/12/202413h30PR Newswire (US)Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
13/12/202423h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
13/12/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
02/12/202413h30PR Newswire (US)HyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentNASDAQ:SNGXSoligenix Inc
19/11/202413h30PR Newswire (US)Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
14/11/202413h15PR Newswire (US)Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
08/11/202422h14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
08/11/202422h12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
08/11/202422h10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
08/11/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
08/11/202413h30PR Newswire (US)Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
24/10/202413h30GlobeNewswire Inc.Soligenix, Inc. to Present at the 2024 ThinkEquity ConferenceNASDAQ:SNGXSoligenix Inc
22/10/202413h30PR Newswire (US)Soligenix Receives Hong Kong Patent for Improved Production of Synthetic HypericinNASDAQ:SNGXSoligenix Inc
16/10/202413h30PR Newswire (US)Soligenix Invited to Present at Upcoming Investor ConferencesNASDAQ:SNGXSoligenix Inc
11/10/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
07/10/202413h30PR Newswire (US)HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferenceNASDAQ:SNGXSoligenix Inc
03/10/202413h30PR Newswire (US)Soligenix Announces Partnership with Sterling Pharma SolutionsNASDAQ:SNGXSoligenix Inc
16/09/202413h30PR Newswire (US)Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024NASDAQ:SNGXSoligenix Inc
03/09/202413h30PR Newswire (US)Soligenix Receives European Patent for Improved Production of Synthetic HypericinNASDAQ:SNGXSoligenix Inc
16/08/202422h19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SNGXSoligenix Inc
16/08/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
09/08/202422h09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
09/08/202422h07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNGX

Kürzlich von Ihnen besucht

BIT
UB8LJB
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten